Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a ...

Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor ...

Had they included just one of Tony Hoare’s achievements, many scientific careers would be considered prestigious enough. His had a long list, unfortunately closed by his passing away at the age of 92 ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reports its first AI enabled clinical proof of concept in familial adenomatous polyposis. The company advances five clinical programs, signaling broader use ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 11 most popular AI penny stocks to buy now. On February 25, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) reported Q4 revenue of $35.5 million ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous polyposis. The company records milestone progress across its collaborations ...

Costumed beasts and creepy crawlies aren’t limited to Halloween. This week a wild and woolly band of bloodthirsty space ...

In the last few years, Chinese AI startup MiniMax has become one of the most exciting in the crowded global AI marketplace, ...

DENVER, March 16, 2026 (GLOBE NEWSWIRE) -- When Jensen Huang talks about the future of technology, markets tend to listen. After leading NVIDIA (NASDAQ:NVDA) to become one of the most valuable ...

The judge said he didn't follow the correct procedure for what is effectively a move to deny patients care.